For research use only, not for therapeutic use.
SX-682（Cat No.:I008854）is a selective dual inhibitor of the chemokine receptors CXCR1 and CXCR2, which play a key role in tumor progression, inflammation, and immune cell recruitment. By blocking these receptors, SX-682 disrupts the signaling pathways that promote the infiltration of immunosuppressive cells like myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment. This enhances the body’s immune response against cancer cells, making SX-682 a promising agent in cancer immunotherapy. Its potential to improve the efficacy of checkpoint inhibitors and other therapies is under active investigation in clinical research.
| Catalog Number | I008854 |
| CAS Number | 1648843-04-2 |
| Synonyms | SX-682; SX 682; SX682.;(2-(((5-((4-fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid |
| Molecular Formula | C19H14BF4N3O4S |
| Purity | ≥95% |
| Target | Cxcr1/2 inhibitor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”>SX-682 is an <span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Interleukin 8A/B receptor antagonist. </span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Phase-I clinical trials in Pancreatic cancer (Combination therapy, Metastatic disease, First-line therapy) in USA (PO, Pill) (NCT04477343) are ongoing.</span></span></span></span> |
| IUPAC Name | [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid |
| InChI | InChI=1S/C19H14BF4N3O4S/c21-13-1-3-14(4-2-13)27-17(28)12-8-25-18(26-9-12)32-10-11-7-15(31-19(22,23)24)5-6-16(11)20(29)30/h1-9,29-30H,10H2,(H,27,28) |
| InChIKey | SDUDZBCEHIZMFZ-UHFFFAOYSA-N |
| SMILES | B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O |
| Reference | <br /> |
